Ancora Advisors LLC Boosts Holdings in Enovis Corporation $ENOV

Key Points

• Ancora Advisors LLC increased its position in Enovis Corporation's stock by 23.6%, owning 241,778 shares valued at approximately $9.24 million as of the end of the most recent quarter.
• Enovis reported $0.79 earnings per share for the most recent quarter, exceeding analysts' expectations, with revenue reaching $564.5 million, a 7.5% increase from the previous year.
• Analyst price targets for Enovis have been generally revised downward, with average targets ranging from $46 to $58, but the stock retains an average rating of "Buy".

Ancora Advisors LLC raised its holdings in shares of Enovis Corporation (NYSE:ENOV - Free Report) by 23.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 241,778 shares of the company's stock after purchasing an additional 46,147 shares during the quarter. Ancora Advisors LLC owned approximately 0.42% of Enovis worth $9,238,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in ENOV. Farther Finance Advisors LLC lifted its holdings in Enovis by 266.7% during the first quarter. Farther Finance Advisors LLC now owns 737 shares of the company's stock valued at $27,000 after purchasing an additional 536 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Enovis by 144.8% during the first quarter. GAMMA Investing LLC now owns 1,170 shares of the company's stock valued at $45,000 after purchasing an additional 692 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in Enovis by 57.7% during the first quarter. DekaBank Deutsche Girozentrale now owns 1,981 shares of the company's stock valued at $74,000 after purchasing an additional 725 shares during the last quarter. McIlrath & Eck LLC purchased a new stake in Enovis during the fourth quarter valued at about $152,000. Finally, Cullen Frost Bankers Inc. purchased a new stake in Enovis during the first quarter valued at about $198,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Trading Down 2.7%

NYSE:ENOV traded down $0.86 during trading hours on Monday, hitting $31.27. The company had a trading volume of 165,188 shares, compared to its average volume of 1,177,950. The company has a market capitalization of $1.79 billion, a PE ratio of -2.19 and a beta of 1.68. The stock has a 50-day moving average price of $30.02 and a 200 day moving average price of $33.03. Enovis Corporation has a 52 week low of $25.47 and a 52 week high of $49.83. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.05. The business had revenue of $564.50 million for the quarter, compared to analysts' expectations of $555.80 million. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. The firm's revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.62 earnings per share. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. On average, equities research analysts predict that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. UBS Group lowered their price target on shares of Enovis from $65.00 to $57.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Needham & Company LLC lowered their price target on shares of Enovis from $57.00 to $49.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Canaccord Genuity Group lowered their price target on shares of Enovis from $70.00 to $58.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Evercore ISI lowered their target price on shares of Enovis from $48.00 to $46.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Finally, Wells Fargo & Company lowered their target price on shares of Enovis from $48.00 to $41.00 and set an "overweight" rating on the stock in a research note on Friday, August 8th. Six analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $51.00.

Insider Buying and Selling at Enovis

In other news, SVP Bradley J. Tandy acquired 3,200 shares of the stock in a transaction on Friday, August 22nd. The stock was acquired at an average price of $31.41 per share, with a total value of $100,512.00. Following the completion of the transaction, the senior vice president owned 43,515 shares of the company's stock, valued at $1,366,806.15. This represents a 7.94% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Phillip Benjamin (Ben) Berry acquired 2,500 shares of the stock in a transaction on Wednesday, August 20th. The shares were purchased at an average cost of $29.71 per share, with a total value of $74,275.00. Following the transaction, the chief financial officer directly owned 116,729 shares of the company's stock, valued at approximately $3,468,018.59. This trade represents a 2.19% increase in their position. The disclosure for this purchase can be found here. Company insiders own 2.70% of the company's stock.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.